October 5, 2018 06:27 AM EDT

From mega-round to $172M IPO in weeks, Orchard is bundling cash to back its play on GSK's gene therapy cast-offs

John Carroll

Editor & Founder

A few weeks ago, when Orchard Therapeutics followed its much buzzed about negotiations to carve out GlaxoSmithKline’s gene therapy operations with a $150 million mega …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

From mega-round to $172M IPO in weeks, Orchard is bundling cash to back its play on GSK's gene therapy cast-offs

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

From mega-round to $172M IPO in weeks, Or­chard is bundling cash to back its play on GSK's gene ther­a­py cast-offs

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

From mega-round to $172M IPO in weeks, Orchard is bundling cash to back its play on GSK's gene therapy cast-offs

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Applied Therapeutics' rare disease drug gets a CRL

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya